Nanotechnology-based Drug Delivery for Alzheimer's and Parkinson's Diseases

Feigin, V.L.; Nichols, E.; Alam, T.; Bannick, M.S.; Beghi, E.; Blake, N.; Culpepper, W.J.; Dorsey, E.R.; Elbaz, A.; Ellenbogen, R.G.; Fisher, J.L.; Fitzmaurice, C.; Giussani, G.; Glennie, L.; James, S.L.; Johnson, C.O.; Kassebaum, N.J.; Logroscino, G.; Marin, B.; Mountjoy-Venning, W.C.; Nguyen, M.; Ofori-Asenso, R.; Patel, A.P.; Piccininni, M.; Roth, G.A.; Steiner, T.J.; Stovner, L.J.; Szoeke, C.E.I.; Theadom, A.; Vollset, S.E.; Wallin, M.T.; Wright, C.; Zunt, J.R.; Abbasi, N.; Abd-Allah, F.; Abdelalim, A.; Abdollahpour, I.; Aboyans, V.; Abraha, H.N.; Acharya, D.; Adamu, A.A.; Adebayo, O.M.; Adeoye, A.M.; Adsuar, J.C.; Afarideh, M.; Agrawal, S.; Ahmadi, A.; Ahmed, M.B.; Aichour, A.N.; Aichour, I.; Aichour, M.T.E.; Akinyemi, R.O.; Akseer, N.; Al-Eyadhy, A.; Al-Shahi Salman, R.; Alahdab, F.; Alene, K.A.; Aljunid, S.M.; Altirkawi, K.; Alvis-Guzman, N.; Anber, N.H.; Antonio, C.A.T.; Arabloo, J.; Aremu, O.; Ärnlöv, J.; Asayesh, H.; Asghar, R.J.; Atalay, H.T.; Awasthi, A.; Ayala Quintanilla, B.P.; Ayuk, T.B.; Badawi, A.; Banach, M.; Banoub, J.A.M.; Barboza, M.A.; Barker-Collo, S.L.; Bärnighausen, T.W.; Baune, B.T.; Bedi, N.; Behzadifar, M.; Behzadifar, M.; Béjot, Y.; Bekele, B.B.; Belachew, A.B.; Bennett, D.A.; Bensenor, I.M.; Berhane, A.; Beuran, M.; Bhattacharyya, K.; Bhutta, Z.A.; Biadgo, B.; Bijani, A.; Bililign, N.; Bin Sayeed, M.S.; Blazes, C.K.; Brayne, C.; Butt, Z.A.; Campos-Nonato, I.R.; Cantu-Brito, C.; Car, M.; Cárdenas, R.; Carrero, J.J.; Carvalho, F.; Castañeda-Orjuela, C.A.; Castro, F.; Catalá-López, F.; Cerin, E.; Chaiah, Y.; Chang, J-C.; Chatziralli, I.; Chiang, P.P-C.; Christensen, H.; Christopher, D.J.; Cooper, C.; Cortesi, P.A.; Costa, V.M.; Criqui, M.H.; Crowe, C.S.; Damasceno, A.A.M.; Daryani, A.; De la Cruz-Góngora, V.; De la Hoz, F.P.; De Leo, D.; Demoz, G.T.; Deribe, K.; Dharmaratne, S.D.; Diaz, D.; Dinberu, M.T.; Djalalinia, S.; Doku, D.T.; Dubey, M.; Dubljanin, E.; Duken, E.E.; Edvardsson, D.; El-Khatib, Z.; Endres, M.; Endries, A.Y.; Eskandarieh, S.; Esteghamati, A.; Esteghamati, S.; Farhadi, F.; Faro, A.; Farzadfar, F.; Farzaei, M.H.; Fatima, B.; Fereshtehnejad, S-M.; Fernandes, E.; Feyissa, G.T.; Filip, I.; Fischer, F.; Fukumoto, T.; Ganji, M.; Gankpe, F.G.; Garcia-Gordillo, M.A.; Gebre, A.K.; Gebremichael, T.G.; Gelaw, B.K.; Geleijnse, J.M.; Geremew, D.; Gezae, K.E.; Ghasemi-Kasman, M.; Gidey, M.Y.; Gill, P.S.; Gill, T.K.; Girma, E.T.; Gnedovskaya, E.V.; Goulart, A.C.; Grada, A.; Grosso, G.; Guo, Y.; Gupta, R.; Gupta, R.; Haagsma, J.A.; Hagos, T.B.; Haj-Mirzaian, A.; Haj-Mirzaian, A.; Hamadeh, R.R.; Hamidi, S.; Hankey, G.J.; Hao, Y.; Haro, J.M.; Hassankhani, H.; Hassen, H.Y.; Havmoeller, R.; Hay, S.I.; Hegazy, M.I.; Heidari, B.; Henok, A.; Heydarpour, F.; Hoang, C.L.; Hole, M.K.; Homaie Rad, E.; Hosseini, S.M.; Hu, G.; Igumbor, E.U.; Ilesanmi, O.S.; Irvani, S.S.N.; Islam, S.M.S.; Jakovljevic, M.; Javanbakht, M.; Jha, R.P.; Jobanputra, Y.B.; Jonas, J.B.; Jozwiak, J.J.; Jürisson, M.; Kahsay, A.; Kalani, R.; Kalkonde, Y.; Kamil, T.A.; Kanchan, T.; Karami, M.; Karch, A.; Karimi, N.; Kasaeian, A.; Kassa, T.D.; Kassa, Z.Y.; Kaul, A.; Kefale, A.T.; Keiyoro, P.N.; Khader, Y.S.; Khafaie, M.A.; Khalil, I.A.; Khan, E.A.; Khang, Y-H.; Khazaie, H.; Kiadaliri, A.A.; Kiirithio, D.N.; Kim, A.S.; Kim, D.; Kim, Y-E.; Kim, Y.J.; Kisa, A.; Kokubo, Y.; Koyanagi, A.; Krishnamurthi, R.V.; Kuate Defo, B.; Kucuk Bicer, B.; Kumar, M.; Lacey, B.; Lafranconi, A.; Lansingh, V.C.; Latifi, A.; Leshargie, C.T.; Li, S.; Liao, Y.; Linn, S.; Lo, W.D.; Lopez, J.C.F.; Lorkowski, S.; Lotufo, P.A.; Lucas, R.M.; Lunevicius, R.; Mackay, M.T.; Mahotra, N.B.; Majdan, M.; Majdzadeh, R.; Majeed, A.; Malekzadeh, R.; Malta, D.C.; Manafi, N.; Mansournia, M.A.; Mantovani, L.G.; März, W.; Mashamba-Thompson, T.P.; Massenburg, B.B.; Mate, K.K.V.; McAlinden, C.; McGrath, J.J.; Mehta, V.; Meier, T.; Meles, H.G.; Melese, A.; Memiah, P.T.N.; Memish, Z.A.; Mendoza, W.; Mengistu, D.T.; Mengistu, G.; Meretoja, A.; Meretoja, T.J.; Mestrovic, T.; Miazgowski, B.; Miazgowski, T.; Miller, T.R.; Mini, G.K.; Mirrakhimov, E.M.; Moazen, B.; Mohajer, B.; Mohammad Gholi Mezerji, N.; Mohammadi, M.; Mohammadi-Khanaposhtani, M.; Mohammadibakhsh, R.; Mohammadnia-Afrouzi, M.; Mohammed, S.; Mohebi, F.; Mokdad, A.H.; Monasta, L.; Mondello, S.; Moodley, Y.; Moosazadeh, M.; Moradi, G.; Moradi-Lakeh, M.; Moradinazar, M.; Moraga, P.; Moreno Velásquez, I.; Morrison, S.D.; Mousavi, S.M.; Muhammed, O.S.; Muruet, W.; Musa, K.I.; Mustafa, G.; Naderi, M.; Nagel, G.; Naheed, A.; Naik, G.; Najafi, F.; Nangia, V.; Negoi, I.; Negoi, R.I.; Newton, C.R.J.; Ngunjiri, J.W.; Nguyen, C.T.; Nguyen, L.H.; Ningrum, D.N.A.; Nirayo, Y.L.; Nixon, M.R.; Norrving, B.; Noubiap, J.J.; Nourollahpour Shiadeh, M.; Nyasulu, P.S.; Ogah, O.S.; Oh, I-H.; Olagunju, A.T.; Olagunju, T.O.; Olivares, P.R.; Onwujekwe, O.E.; Oren, E.; Owolabi, M.O.; Pa, M.; Pakpour, A.H.; Pan, W-H.; Panda-Jonas, S.; Pandian, J.D.; Patel, S.K.; Pereira, D.M.; Petzold, M.; Pillay, J.D.; Piradov, M.A.; Polanczyk, G.V.; Polinder, S.; Postma, M.J.; Poulton, R.; Poustchi, H.; Prakash, S.; Prakash, V.; Qorbani, M.; Radfar, A.; Rafay, A.; Rafiei, A.; Rahim, F.; Rahimi-Movaghar, V.; Rahman, M.; Rahman, M.H.U.; Rahman, M.A.; Rajati, F.; Ram, U.; Ranta, A.; Rawaf, D.L.; Rawaf, S.; Reinig, N.; Reis, C.; Renzaho, A.M.N.; Resnikoff, S.; Rezaeian, S.; Rezai, M.S.; Rios González, C.M.; Roberts, N.L.S.; Roever, L.; Ronfani, L.; Roro, E.M.; Roshandel, G.; Rostami, A.; Sabbagh, P.; Sacco, R.L.; Sachdev, P.S.; Saddik, B.; Safari, H.; Safari-Faramani, R.; Safi, S.; Safiri, S.; Sagar, R.; Sahathevan, R.; Sahebkar, A.; Sahraian, M.A.; Salamati, P.; Salehi Zahabi, S.; Salimi, Y.; Samy, A.M.; Sanabria, J.; Santos, I.S.; Santric Milicevic, M.M.; Sarrafzadegan, N.; Sartorius, B.; Sarvi, S.; Sathian, B.; Satpathy, M.; Sawant, A.R.; Sawhney, M.; Schneider, I.J.C.; Schöttker, B.; Schwebel, D.C.; Seedat, S.; Sepanlou, S.G.; Shabaninejad, H.; Shafieesabet, A.; Shaikh, M.A.; Shakir, R.A.; Shams-Beyranvand, M.; Shamsizadeh, M.; Sharif, M.; Sharif-Alhoseini, M.; She, J.; Sheikh, A.; Sheth, K.N.; Shigematsu, M.; Shiri, R.; Shirkoohi, R.; Shiue, I.; Siabani, S.; Siddiqi, T.J.; Sigfusdottir, I.D.; Sigurvinsdottir, R.; Silberberg, D.H.; Silva, J.P.; Silveira, D.G.A.; Singh, J.A.; Sinha, D.N.; Skiadaresi, E.; Smith, M.; Sobaih, B.H.; Sobhani, S.; Soofi, M.; Soyiri, I.N.; Sposato, L.A.; Stein, D.J.; Stein, M.B.; Stokes, M.A.; Sufiyan, M.B.; Sykes, B.L.; Sylaja, P.N.; Tabarés-Seisdedos, R.; Te Ao, B.J.; Tehrani-Banihashemi, A.; Temsah, M-H.; Temsah, O.; Thakur, J.S.; Thrift, A.G.; Topor-Madry, R.; Tortajada-Girbés, M.; Tovani-Palone, M.R.; Tran, B.X.; Tran, K.B.; Truelsen, T.C.; Tsadik, A.G.; Tudor Car, L.; Ukwaja, K.N.; Ullah, I.; Usman, M.S.; Uthman, O.A.; Valdez, P.R.; Vasankari, T.J.; Vasanthan, R.; Veisani, Y.; Venketasubramanian, N.; Violante, F.S.; Vlassov, V.; Vosoughi, K.; Vu, G.T.; Vujcic, I.S.; Wagnew, F.S.; Waheed, Y.; Wang, Y-P.; Weiderpass, E.; Weiss, J.; Whiteford, H.A.; Wijeratne, T.; Winkler, A.S.; Wiysonge, C.S.; Wolfe, C.D.A.; Xu, G.; Yadollahpour, A.; Yamada, T.; Yano, Y.; Yaseri, M.; Yatsuya, H.; Yimer, E.M.; Yip, P.; Yisma, E.; Yonemoto, N.; Yousefifard, M.; Yu, C.; Zaidi, Z.; Zaman, S.B.; Zamani, M.; Zandian, H.; Zare, Z.; Zhang, Y.; Zodpey, S.; Naghavi, M.; Murray, C.J.L.; Vos, T. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol., 2019, 18(5), 459-480.
[http://dx.doi.org/10.1016/S1474-4422(18)30499-X] [PMID: 30879893]

Feng, L.; Wang, H.; Xue, X. Recent Progress of Nanomedicine in the Treatment of Central Nervous System Diseases. Adv. Ther. (Weinh.), 2020, 3(5), 1900159.
[http://dx.doi.org/10.1002/adtp.201900159]

Korczyn, A.D.; Reichmann, H.; Boroojerdi, B.; Häck, H.J. Rotigotine transdermal system for perioperative administration. J. Neural Transm. (Vienna), 2007, 114(2), 219-221.
[http://dx.doi.org/10.1007/s00702-006-0606-3] [PMID: 17177076]

Selikhova, M.; Williams, D.R.; Kempster, P.A.; Holton, J.L.; Revesz, T.; Lees, A.J. A clinico-pathological study of subtypes in Parkinson’s disease. Brain, 2009, 132(11), 2947-2957.
[http://dx.doi.org/10.1093/brain/awp234] [PMID: 19759203]

Bonelli, R.M.; Cummings, J.L. Frontal-Subcortical Dementias. Neurologist, 2008, 14(2), 100-107.
[http://dx.doi.org/10.1097/NRL.0b013e31815b0de2] [PMID: 18332839]

Nguyen, T.T.; Nguyen, T.T.D.; Nguyen, T.K.O.; Vo, T.K.; Vo, V.G. Advances in developing therapeutic strategies for Alzheimer’s disease. Biomed. Pharmacother., 2021, 139111623.
[http://dx.doi.org/10.1016/j.biopha.2021.111623] [PMID: 33915504]

Jankovic, J.; Aguilar, L.G. Current approaches to the treatment of Parkinson’s disease. Neuropsychiatr. Dis. Treat., 2008, 4(4), 743-757.
[http://dx.doi.org/10.2147/NDT.S2006] [PMID: 19043519]

Tajes, M.; Ramos-Fernández, E.; Weng-Jiang, X.; Bosch-Morató, M.; Guivernau, B.; Eraso-Pichot, A.; Salvador, B.; Fernàndez-Busquets, X.; Roquer, J.; Muñoz, F.J. The blood-brain barrier: Structure, function and therapeutic approaches to cross it. Mol. Membr. Biol., 2014, 31(5), 152-167.
[http://dx.doi.org/10.3109/09687688.2014.937468] [PMID: 25046533]

Liu, Y.; Zou, Y.; Feng, C.; Lee, A.; Yin, J.; Chung, R.; Park, J.B.; Rizos, H.; Tao, W.; Zheng, M.; Farokhzad, O.C.; Shi, B. Charge Conversional Biomimetic Nanocomplexes as a Multifunctional Platform for Boosting Orthotopic Glioblastoma RNAi Therapy. Nano Lett., 2020, 20(3), 1637-1646.
[http://dx.doi.org/10.1021/acs.nanolett.9b04683] [PMID: 32013452]

Lang, T.; Yin, Q.; Li, Y. Progress of Cell-Derived Biomimetic Drug Delivery Systems for Cancer Therapy. Adv. Ther. (Weinh.), 2018, 1(7), 1800053.
[http://dx.doi.org/10.1002/adtp.201800053]

García, M.C. 4 - Nano- and microparticles as drug carriers.Engineering Drug Delivery Systems; Woodhead Publishing, 2020, pp. 71-110.

Elmowafy, M.; Al-Sanea, M.M. Nanostructured lipid carriers (NLCs) as drug delivery platform: Advances in formulation and delivery strategies. Saudi Pharm. J., 2021, 29(9), 999-1012.
[http://dx.doi.org/10.1016/j.jsps.2021.07.015] [PMID: 34588846]

Kumar, M.; Bishnoi, R.S.; Shukla, A.K.; Jain, C.P. Techniques for Formulation of Nanoemulsion Drug Delivery System: A Review. Prev. Nutr. Food Sci., 2019, 24(3), 225-234.
[http://dx.doi.org/10.3746/pnf.2019.24.3.225] [PMID: 31608247]

Liu, Q.; Kim, Y.J.; Im, G-B.; Zhu, J.; Wu, Y.; Liu, Y.; Bhang, S.H. Inorganic Nanoparticles Applied as Functional Therapeutics. Adv. Funct. Mater., 2021, 31(12), 2008171.
[http://dx.doi.org/10.1002/adfm.202008171]

Heuer-Jungemann, A.; Linko, V. Engineering Inorganic Materials with DNA Nanostructures. ACS Cent. Sci., 2021, 7(12), 1969-1979.
[http://dx.doi.org/10.1021/acscentsci.1c01272] [PMID: 34963890]

Sanità, G.; Carrese, B.; Lamberti, A. Nanoparticle Surface Functionalization: How to Improve Biocompatibility and Cellular Internalization. Front. Mol. Biosci., 2020, 7587012.
[http://dx.doi.org/10.3389/fmolb.2020.587012] [PMID: 33324678]

Nair, M.; Jayant, R.D.; Kaushik, A.; Sagar, V. Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS. Adv. Drug Deliv. Rev., 2016, 103, 202-217.
[http://dx.doi.org/10.1016/j.addr.2016.02.008] [PMID: 26944096]

Pardridge, W.M. Drug transport across the blood-brain barrier. J. Cereb. Blood Flow Metab., 2012, 32(11), 1959-1972.
[http://dx.doi.org/10.1038/jcbfm.2012.126] [PMID: 22929442]

Grabrucker, A.M.; Ruozi, B.; Belletti, D.; Pederzoli, F.; Forni, F.; Vandelli, M.A.; Tosi, G. Nanoparticle transport across the blood brain barrier. Tissue Barriers, 2016, 4(1), e1153568.
[http://dx.doi.org/10.1080/21688370.2016.1153568] [PMID: 27141426]

Jones, A.R.; Shusta, E.V. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm. Res., 2007, 24(9), 1759-1771.
[http://dx.doi.org/10.1007/s11095-007-9379-0] [PMID: 17619996]

Saraiva, C.; Praça, C.; Ferreira, R.; Santos, T.; Ferreira, L.; Bernardino, L. Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases. J. Control. Release, 2016, 235, 34-47.
[http://dx.doi.org/10.1016/j.jconrel.2016.05.044] [PMID: 27208862]

Ingusci, S.; Verlengia, G.; Soukupova, M.; Zucchini, S.; Simonato, M. Gene Therapy Tools for Brain Diseases. Front. Pharmacol., 2019, 10, 724.
[http://dx.doi.org/10.3389/fphar.2019.00724] [PMID: 31312139]

Ribeiro, M.M.B.; Domingues, M.M.; Freire, J.M.; Santos, N.C.; Castanho, M.A.R.B. Translocating the blood-brain barrier using electrostatics. Front. Cell. Neurosci., 2012, 6, 44.
[http://dx.doi.org/10.3389/fncel.2012.00044] [PMID: 23087614]

Zhang, W.; Mehta, A.; Tong, Z.; Esser, L.; Voelcker, N.H. Development of Polymeric Nanoparticles for Blood–Brain Barrier Transfer—Strategies and Challenges. Adv. Sci. (Weinh.), 2021, 8(10), 2003937.
[http://dx.doi.org/10.1002/advs.202003937] [PMID: 34026447]

Johnsen, KB; Bak, M; Melander, F; Thomsen, MS; Burkhart, A; Kempen, PJ Modulating the antibody density changes the uptake and transport at the blood-brain barrier of both transferrin receptortargeted gold nanoparticles and liposomal cargo. J. contr. rel., 2019, 295, 237-249.
[http://dx.doi.org/10.1016/j.jconrel.2019.01.005]

Hersh, A.M.; Alomari, S.; Tyler, B.M. Crossing the Blood-Brain Barrier: Advances in Nanoparticle Technology for Drug Delivery in Neuro-Oncology. Int. J. Mol. Sci., 2022, 23(8), 4153.
[http://dx.doi.org/10.3390/ijms23084153] [PMID: 35456971]

Jain, K.K. Nanobiotechnology-based drug delivery to the central nervous system. Neurodegener. Dis., 2007, 4(4), 287-291.
[http://dx.doi.org/10.1159/000101884] [PMID: 17627131]

Cummings, J.L. Alzheimer’s Disease. N. Engl. J. Med., 2004, 351(1), 56-67.
[http://dx.doi.org/10.1056/NEJMra040223] [PMID: 15229308]

Jakob-Roetne, R.; Jacobsen, H. Alzheimer’s disease: from pathology to therapeutic approaches. Angew. Chem. Int. Ed., 2009, 48(17), 3030-3059.
[http://dx.doi.org/10.1002/anie.200802808] [PMID: 19330877]

Nguyen, T.T.; Ta, Q.T.H.; Nguyen, T.T.D.; Le, T.T.; Vo, V.G. Role of Insulin Resistance in the Alzheimer’s Disease Progression. Neurochem. Res., 2020, 45(7), 1481-1491.
[http://dx.doi.org/10.1007/s11064-020-03031-0] [PMID: 32314178]

Nguyen, T.T.; Ta, Q.T.H.; Nguyen, T.K.O.; Nguyen, T.T.D.; Van Giau, V. Type 3 Diabetes and Its Role Implications in Alzheimer’s Disease. Int. J. Mol. Sci., 2020, 21(9), 3165.
[http://dx.doi.org/10.3390/ijms21093165] [PMID: 32365816]

Bagyinszky, E.; Giau, V.V.; Shim, K.; Suk, K.; An, S.S.A.; Kim, S. Role of inflammatory molecules in the Alzheimer’s disease progression and diagnosis. J. Neurol. Sci., 2017, 376, 242-254.
[http://dx.doi.org/10.1016/j.jns.2017.03.031] [PMID: 28431620]

Atri, A. The Alzheimer’s Disease Clinical Spectrum. Med. Clin. North Am., 2019, 103(2), 263-293.
[http://dx.doi.org/10.1016/j.mcna.2018.10.009] [PMID: 30704681]

Thies, W.; Bleiler, L.; Bleiler, L. 2013 Alzheimer’s disease facts and figures. Alzheimers Dement., 2013, 9(2), 208-245.
[http://dx.doi.org/10.1016/j.jalz.2013.02.003] [PMID: 23507120]

Perl, D.P. Neuropathology of Alzheimer’s disease. Mt. Sinai J. Med., 2010, 77(1), 32-42.
[http://dx.doi.org/10.1002/msj.20157] [PMID: 20101720]

Panza, F.; Frisardi, V.; Imbimbo, B.P.; D’Onofrio, G.; Pietrarossa, G.; Seripa, D.; Pilotto, A.; Solfrizzi, V. Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer’s disease. Immunotherapy, 2010, 2(6), 767-782.
[http://dx.doi.org/10.2217/imt.10.80] [PMID: 21091109]

Tayeb, H.O.; Murray, E.D.; Price, B.H.; Tarazi, F.I. Bapineuzumab and solanezumab for Alzheimer’s disease: is the ‘amyloid cascade hypothesis’ still alive? Expert Opin. Biol. Ther., 2013, 13(7), 1075-1084.
[http://dx.doi.org/10.1517/14712598.2013.789856] [PMID: 23574434]

Ostrowitzki, S.; Deptula, D.; Thurfjell, L.; Barkhof, F.; Bohrmann, B.; Brooks, D.J.; Klunk, W.E.; Ashford, E.; Yoo, K.; Xu, Z.X.; Loetscher, H.; Santarelli, L. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch. Neurol., 2012, 69(2), 198-207.
[http://dx.doi.org/10.1001/archneurol.2011.1538] [PMID: 21987394]

Budd Haeberlein, S.; Aisen, P.S.; Barkhof, F.; Chalkias, S.; Chen, T.; Cohen, S.; Dent, G.; Hansson, O.; Harrison, K.; von Hehn, C.; Iwatsubo, T.; Mallinckrodt, C.; Mummery, C.J.; Muralidharan, K.K.; Nestorov, I.; Nisenbaum, L.; Rajagovindan, R.; Skordos, L.; Tian, Y.; van Dyck, C.H.; Vellas, B.; Wu, S.; Zhu, Y.; Sandrock, A. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease. J. Prev. Alzheimers Dis., 2022, 9(2), 197-210.
[PMID: 35542991]

van Dyck, C.H.; Swanson, C.J.; Aisen, P.; Bateman, R.J.; Chen, C.; Gee, M.; Kanekiyo, M.; Li, D.; Reyderman, L.; Cohen, S.; Froelich, L.; Katayama, S.; Sabbagh, M.; Vellas, B.; Watson, D.; Dhadda, S.; Irizarry, M.; Kramer, L.D.; Iwatsubo, T. Lecanemab in Early Alzheimer’s Disease. N. Engl. J. Med., 2023, 388(1), 9-21.
[http://dx.doi.org/10.1056/NEJMoa2212948] [PMID: 36449413]

Song, Q.; Huang, M.; Yao, L.; Wang, X.; Gu, X.; Chen, J.; Chen, J.; Huang, J.; Hu, Q.; Kang, T.; Rong, Z.; Qi, H.; Zheng, G.; Chen, H.; Gao, X. Lipoprotein-based nanoparticles rescue the memory loss of mice with Alzheimer’s disease by accelerating the clearance of amyloid-beta. ACS Nano, 2014, 8(3), 2345-2359.
[http://dx.doi.org/10.1021/nn4058215] [PMID: 24527692]

Dara, T.; Vatanara, A.; Sharifzadeh, M.; Khani, S.; Vakilinezhad, M.A.; Vakhshiteh, F.; Nabi Meybodi, M.; Sadegh Malvajerd, S.; Hassani, S.; Mosaddegh, M.H. Improvement of memory deficits in the rat model of Alzheimer’s disease by erythropoietin-loaded solid lipid nanoparticles. Neurobiol. Learn. Mem., 2019, 166107082.
[http://dx.doi.org/10.1016/j.nlm.2019.107082] [PMID: 31493483]

Mohamadpour, H.; Azadi, A.; Rostamizadeh, K.; Andalib, S.; Saghatchi Zanjani, M.R.; Hamidi, M. Preparation, Optimization, and Evaluation of Methoxy Poly(ethylene glycol)- co -Poly(ε-caprolactone) Nanoparticles Loaded by Rivastigmine for Brain Delivery. ACS Chem. Neurosci., 2020, 11(5), 783-795.
[http://dx.doi.org/10.1021/acschemneuro.9b00691] [PMID: 32043866]

Sonawane, S.K.; Ahmad, A.; Chinnathambi, S. Protein-Capped Metal Nanoparticles Inhibit Tau Aggregation in Alzheimer’s Disease. ACS Omega, 2019, 4(7), 12833-12840.
[http://dx.doi.org/10.1021/acsomega.9b01411] [PMID: 31460408]

Han, Y.; Gao, C.; Wang, H.; Sun, J.; Liang, M.; Feng, Y.; Liu, Q.; Fu, S.; Cui, L.; Gao, C.; Li, Y.; Yang, Y.; Sun, B. Macrophage membrane-coated nanocarriers Co-Modified by RVG29 and TPP improve brain neuronal mitochondria-targeting and therapeutic efficacy in Alzheimer’s disease mice. Bioact. Mater., 2021, 6(2), 529-542.
[http://dx.doi.org/10.1016/j.bioactmat.2020.08.017] [PMID: 32995678]

Burilova, E.A.; Pashirova, T.N.; Zueva, I.V.; Gibadullina, E.M.; Lushchekina, S.V.; Sapunova, A.S.; Kayumova, R.M.; Rogov, A.M.; Evtjugin, V.G.; Sudakov, I.A.; Vyshtakalyuk, A.B.; Voloshina, A.D.; Bukharov, S.V.; Burilov, A.R.; Petrov, K.A.; Zakharova, L.Y.; Sinyashin, O.G. Bi-functional sterically hindered phenol lipid-based delivery systems as potential multi-target agents against Alzheimer’s disease via an intranasal route. Nanoscale, 2020, 12(25), 13757-13770.
[http://dx.doi.org/10.1039/D0NR04037A] [PMID: 32573587]

Krishna, K.V.; Wadhwa, G.; Alexander, A.; Kanojia, N.; Saha, R.N.; Kukreti, R.; Singhvi, G.; Dubey, S.K. Design and Biological Evaluation of Lipoprotein-Based Donepezil Nanocarrier for Enhanced Brain Uptake through Oral Delivery. ACS Chem. Neurosci., 2019, 10(9), 4124-4135.
[http://dx.doi.org/10.1021/acschemneuro.9b00343] [PMID: 31418556]

AnjiReddy, K.; Karpagam, S. Chitosan nanofilm and electrospun nanofiber for quick drug release in the treatment of Alzheimer’s disease: In vitro and in vivo evaluation. Int. J. Biol. Macromol., 2017, 105(Pt 1), 131-142.
[http://dx.doi.org/10.1016/j.ijbiomac.2017.07.021] [PMID: 28698078]

Pagar, K.P.; Sardar, S.M.; Vavia, P.R. Novel L-lactide-depsipeptide polymeric carrier for enhanced brain uptake of rivastigmine in treatment of Alzheimer’s disease. J. Biomed. Nanotechnol., 2014, 10(3), 415-426.
[http://dx.doi.org/10.1166/jbn.2014.1719] [PMID: 24730237]

Md, S.; Ali, M.; Baboota, S.; Sahni, J.K.; Bhatnagar, A.; Ali, J. Preparation, characterization, in vivo biodistribution and pharmacokinetic studies of donepezil-loaded PLGA nanoparticles for brain targeting. Drug Dev. Ind. Pharm., 2014, 40(2), 278-287.
[http://dx.doi.org/10.3109/03639045.2012.758130] [PMID: 23369094]

Fazil, M.; Md, S.; Haque, S.; Kumar, M.; Baboota, S.; Sahni, J.; Ali, J. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur. J. Pharm. Sci., 2012, 47(1), 6-15.
[http://dx.doi.org/10.1016/j.ejps.2012.04.013] [PMID: 22561106]

Cabaleiro-Lago, C.; Quinlan-Pluck, F.; Lynch, I.; Dawson, K.A.; Linse, S. Dual effect of amino modified polystyrene nanoparticles on amyloid β protein fibrillation. ACS Chem. Neurosci., 2010, 1(4), 279-287.
[http://dx.doi.org/10.1021/cn900027u] [PMID: 22778827]

Luo, J.; Wärmländer, S.K.T.S.; Yu, C.H.; Muhammad, K.; Gräslund, A.; Pieter Abrahams, J. The Aβ peptide forms non-amyloid fibrils in the presence of carbon nanotubes. Nanoscale, 2014, 6(12), 6720-6726.
[http://dx.doi.org/10.1039/C4NR00291A] [PMID: 24820873]

Fu, Z.; Luo, Y.; Derreumaux, P.; Wei, G. Induced β-Barrel Formation of the Alzheimer’s Aβ25–35 Oligomers on Carbon Nanotube Surfaces: Implication for Amyloid Fibril Inhibition Biophys. J., 2009, 97(6), 1795-1803.
[http://dx.doi.org/10.1016/j.bpj.2009.07.014] [PMID: 19751686]

Poewe, W.; Seppi, K.; Tanner, C.M.; Halliday, G.M.; Brundin, P.; Volkmann, J.; Schrag, A.E.; Lang, A.E. Parkinson disease. Nat. Rev. Dis. Primers, 2017, 3(1), 17013.
[http://dx.doi.org/10.1038/nrdp.2017.13] [PMID: 28332488]

Stefanis, L. α-Synuclein in Parkinson’s disease. Cold Spring Harb. Perspect. Med., 2012, 2(2), a009399.
[http://dx.doi.org/10.1101/cshperspect.a009399] [PMID: 22355802]

Pillay, S.; Pillay, V.; Choonara, Y.E.; Naidoo, D.; Khan, R.A.; du Toit, L.C.; Ndesendo, V.M.K.; Modi, G.; Danckwerts, M.P.; Iyuke, S.E. Design, biometric simulation and optimization of a nano-enabled scaffold device for enhanced delivery of dopamine to the brain. Int. J. Pharm., 2009, 382(1-2), 277-290.
[http://dx.doi.org/10.1016/j.ijpharm.2009.08.021] [PMID: 19703530]

Yoosefian, M.; Rahmanifar, E.; Etminan, N. Nanocarrier for levodopa Parkinson therapeutic drug; comprehensive benserazide analysis. Artif. Cells Nanomed. Biotechnol., 2018, 46, 434-446.

Fernandes, C.; Martins, C.; Fonseca, A.; Nunes, R.; Matos, M.J.; Silva, R.; Garrido, J.; Sarmento, B.; Remião, F.; Otero-Espinar, F.J.; Uriarte, E.; Borges, F. PEGylated PLGA Nanoparticles As a Smart Carrier to Increase the Cellular Uptake of a Coumarin-Based Monoamine Oxidase B Inhibitor. ACS Appl. Mater. Interfaces, 2018, 10(46), 39557-39569.
[http://dx.doi.org/10.1021/acsami.8b17224] [PMID: 30352150]

Kundu, P.; Das, M.; Tripathy, K.; Sahoo, S.K. Delivery of Dual Drug Loaded Lipid Based Nanoparticles across the Blood–Brain Barrier Impart Enhanced Neuroprotection in a Rotenone Induced Mouse Model of Parkinson’s Disease. ACS Chem. Neurosci., 2016, 7(12), 1658-1670.
[http://dx.doi.org/10.1021/acschemneuro.6b00207] [PMID: 27642670]

Li, Y.; Chen, Z.; Lu, Z.; Yang, Q.; Liu, L.; Jiang, Z.; Zhang, L.; Zhang, X.; Qing, H. “Cell-addictive” dual-target traceable nanodrug for Parkinson’s disease treatment via flotillins pathway. Theranostics, 2018, 8(19), 5469-5481.
[http://dx.doi.org/10.7150/thno.28295] [PMID: 30555558]

Zhao, N.; Yang, X.; Calvelli, H.R.; Cao, Y.; Francis, N.L.; Chmielowski, R.A.; Joseph, L.B.; Pang, Z.P.; Uhrich, K.E.; Baum, J.; Moghe, P.V. Antioxidant Nanoparticles for Concerted Inhibition of α-Synuclein Fibrillization, and Attenuation of Microglial Intracellular Aggregation and Activation. Front. Bioeng. Biotechnol., 2020, 8, 112.
[http://dx.doi.org/10.3389/fbioe.2020.00112] [PMID: 32154238]

Manfredsson, F.P.; Lewin, A.S.; Mandel, R.J. RNA knockdown as a potential therapeutic strategy in Parkinson’s disease. Gene Ther., 2006, 13(6), 517-524.
[http://dx.doi.org/10.1038/sj.gt.3302669] [PMID: 16267570]

Hu, K.; Chen, X.; Chen, W.; Zhang, L.; Li, J.; Ye, J.; Zhang, Y.; Zhang, L.; Li, C.H.; Yin, L.; Guan, Y.Q. Neuroprotective effect of gold nanoparticles composites in Parkinson’s disease model. Nanomedicine, 2018, 14(4), 1123-1136.
[http://dx.doi.org/10.1016/j.nano.2018.01.020] [PMID: 29474924]

Wang, W.; Zheng, J.; Zhou, H.; Liu, Q.; Jia, L.; Zhang, X.; Ge, D.; Shi, W.; Sun, Y. Polydopamine-Based Nanocomposite as a Biomimetic Antioxidant with a Variety of Enzymatic Activities for Parkinson’s Disease. ACS Appl. Mater. Interfaces, 2022, 14(29), 32901-32913.
[http://dx.doi.org/10.1021/acsami.2c06981] [PMID: 35820068]

Khanam, S.; Naz, F.; Ali, F.; Smita Jyoti, R.; Fatima, A.; Khan, W.; Singh, B.R.; Naqvi, A.H.; Siddique, Y.H. Effect of cabergoline alginate nanocomposite on the transgenic Drosophila melanogaster model of Parkinson’s disease. Toxicol. Mech. Methods, 2018, 28(9), 699-708.
[http://dx.doi.org/10.1080/15376516.2018.1502386] [PMID: 30019977]

Umarao, P.; Bose, S.; Bhattacharyya, S.; Kumar, A.; Jain, S. Neuroprotective Potential of Superparamagnetic Iron Oxide Nanoparticles Along with Exposure to Electromagnetic Field in 6-OHDA Rat Model of Parkinson’s Disease. J. Nanosci. Nanotechnol., 2016, 16(1), 261-269.
[http://dx.doi.org/10.1166/jnn.2016.11103] [PMID: 27398453]

Kwon, H.J.; Cha, M.Y.; Kim, D.; Kim, D.K.; Soh, M.; Shin, K.; Hyeon, T.; Mook-Jung, I. Mitochondria-Targeting Ceria Nanoparticles as Antioxidants for Alzheimer’s Disease. ACS Nano, 2016, 10(2), 2860-2870.
[http://dx.doi.org/10.1021/acsnano.5b08045] [PMID: 26844592]

Kwon, H.J.; Kim, D.; Seo, K.; Kim, Y.G.; Han, S.I.; Kang, T.; Soh, M.; Hyeon, T. Ceria Nanoparticle Systems for Selective Scavenging of Mitochondrial, Intracellular, and Extracellular Reactive Oxygen Species in Parkinson’s Disease. Angew. Chem. Int. Ed., 2018, 57(30), 9408-9412.
[http://dx.doi.org/10.1002/anie.201805052] [PMID: 29862623]

Sarkar, S.; Raymick, J.; Imam, S. Neuroprotective and Therapeutic Strategies against Parkinson’s Disease: Recent Perspectives. Int. J. Mol. Sci., 2016, 17(6), 904.
[http://dx.doi.org/10.3390/ijms17060904] [PMID: 27338353]

Herrán, E.; Ruiz-Ortega, J.Á.; Aristieta, A.; Igartua, M.; Requejo, C.; Lafuente, J.V.; Ugedo, L.; Pedraz, J.L.; Hernández, R.M. In vivo administration of VEGF- and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson’s disease. Eur. J. Pharm. Biopharm., 2013, 85(3)(3 Pt B), 1183-1190.
[http://dx.doi.org/10.1016/j.ejpb.2013.03.034] [PMID: 23639739]

Wang, X.S.; Zhang, Z.R.; Zhang, M.M.; Sun, M.X.; Wang, W.W.; Xie, C.L. Neuroprotective properties of curcumin in toxin-base animal models of Parkinson’s disease: a systematic experiment literatures review. BMC Complement. Altern. Med., 2017, 17(1), 412.
[http://dx.doi.org/10.1186/s12906-017-1922-x] [PMID: 28818104]

da Rocha Lindner, G.; Bonfanti Santos, D.; Colle, D.; Gasnhar Moreira, E.L.; Daniel Prediger, R.; Farina, M.; Khalil, N.M.; Mara Mainardes, R. Improved neuroprotective effects of resveratrol-loaded polysorbate 80-coated poly(lactide) nanoparticles in MPTP-induced Parkinsonism. Nanomedicine (Lond.), 2015, 10(7), 1127-1138.
[http://dx.doi.org/10.2217/nnm.14.165] [PMID: 25929569]

Esteves, M.; Cristóvão, A.C.; Saraiva, T.; Rocha, S.M.; Baltazar, G.; Ferreira, L.; Bernardino, L. Retinoic acid-loaded polymeric nanoparticles induce neuroprotection in a mouse model for Parkinson’s disease. Front. Aging Neurosci., 2015, 7, 20.
[http://dx.doi.org/10.3389/fnagi.2015.00020] [PMID: 25798108]

Johnsen, K.B.; Burkhart, A.; Melander, F.; Kempen, P.J.; Vejlebo, J.B.; Siupka, P.; Nielsen, M.S.; Andresen, T.L.; Moos, T. Targeting transferrin receptors at the blood-brain barrier improves the uptake of immunoliposomes and subsequent cargo transport into the brain parenchyma. Sci. Rep., 2017, 7(1), 10396.
[http://dx.doi.org/10.1038/s41598-017-11220-1] [PMID: 28871203]

Abazari, M.A.; Soltani, M.; Kashkooli, F.M. Targeted nano-sized drug delivery to heterogeneous solid tumor microvasculatures: Implications for immunoliposomes exhibiting bystander killing effect. Phys. Fluids, 2023, 35(1), 011905.
[http://dx.doi.org/10.1063/5.0130259]

Nguyen, T.T.; Dung Nguyen, T.T.; Vo, T.K.; Tran, N.M.; Nguyen, M.K.; Van Vo, T. Nanotechnology-based drug delivery for central nervous system disorders. Biomed. pharmacoth., 2021, 143, p. 112117.
[http://dx.doi.org/10.1016/j.biopha.2021.112117]

Li, A.; Tyson, J.; Patel, S.; Patel, M.; Katakam, S.; Mao, X.; He, W. Emerging Nanotechnology for Treatment of Alzheimer’s and Parkinson’s Disease. Front. Bioeng. Biotechnol., 2021, 96, 72594.
[http://dx.doi.org/10.3389/fbioe.2021.672594] [PMID: 34113606]

Zhong, G.; Long, H.; Zhou, T.; Liu, Y.; Zhao, J.; Han, J.; Yang, X.; Yu, Y.; Chen, F.; Shi, S. Blood-brain barrier Permeable nanoparticles for Alzheimer’s disease treatment by selective mitophagy of microglia. Biomaterials, 2022, 288121690.
[http://dx.doi.org/10.1016/j.biomaterials.2022.121690] [PMID: 35965114]

Pinheiro, R.G.R.; Granja, A.; Loureiro, J.A.; Pereira, M.C.; Pinheiro, M.; Neves, A.R.; Reis, S. Quercetin lipid nanoparticles functionalized with transferrin for Alzheimer’s disease. Eur. J. Pharm. Sci., 2020, 148, 105314.
[http://dx.doi.org/10.1016/j.ejps.2020.105314] [PMID: 32200044]

Pinheiro, R.G.R.; Granja, A.; Loureiro, J.A.; Pereira, M.C.; Pinheiro, M.; Neves, A.R.; Reis, S. RVG29-Functionalized Lipid Nanoparticles for Quercetin Brain Delivery and Alzheimer’s Disease. Pharm. Res., 2020, 37(7), 139.
[http://dx.doi.org/10.1007/s11095-020-02865-1] [PMID: 32661727]

Cai, J.; Dao, P.; Chen, H.; Yan, L.; Li, Y.L.; Zhang, W.; Li, L.; Du, Z.; Dong, C-Z.; Meunier, B. Ultrasmall superparamagnetic iron oxide nanoparticles-bound NIR dyes: Novel theranostic agents for Alzheimer’s disease. Dyes Pigments, 2020, 173, 107968.
[http://dx.doi.org/10.1016/j.dyepig.2019.107968]

Sharma, M.; Tiwari, V.; Shukla, S.; Panda, J.J. Fluorescent Dopamine–Tryptophan Nanocomposites as Dual-Imaging and Antiaggregation Agents: New Generation of Amyloid Theranostics with Trimeric Effects. ACS Appl. Mater. Interfaces, 2020, 12(39), 44180-44194.
[http://dx.doi.org/10.1021/acsami.0c13223] [PMID: 32870652]

Gao, N.; Sun, H.; Dong, K.; Ren, J.; Qu, X. Gold-nanoparticle-based multifunctional amyloid-β inhibitor against Alzheimer’s disease. Chemistry, 2015, 21(2), 829-835.
[http://dx.doi.org/10.1002/chem.201404562] [PMID: 25376633]

Gao, W.; Wang, W.; Dong, X.; Sun, Y. Nitrogen‐Doped Carbonized Polymer Dots: A Potent Scavenger and Detector Targeting Alzheimer’s β. Amyloid Plaques. Small, 2020, 16(43), 2002804.
[http://dx.doi.org/10.1002/smll.202002804] [PMID: 33006250]

Mittapelly, N.; Thalla, M.; Pandey, G.; Banala, V.T.; Sharma, S.; Arya, A.; Mishra, S.; Mitra, K.; Shukla, S.; Mishra, P.R. Long Acting Ionically Paired Embonate Based Nanocrystals of Donepezil for the Treatment of Alzheimer’s Disease: a Proof of Concept Study. Pharm. Res., 2017, 34(11), 2322-2335.
[http://dx.doi.org/10.1007/s11095-017-2240-1] [PMID: 28808833]

Sunena; Singh, S.K.; Mishra, D.N. Nose to Brain Delivery of Galantamine Loaded Nanoparticles: In-vivo Pharmacodynamic and Biochemical Study in Mice. Curr. Drug Deliv., 2018, 16(1), 51-58.
[http://dx.doi.org/10.2174/1567201815666181004094707] [PMID: 30289074]

Misra, S.; Chopra, K.; Saikia, U.N.; Sinha, V.R.; Sehgal, R.; Modi, M.; Medhi, B. Effect of mesenchymal stem cells and galantamine nanoparticles in rat model of Alzheimer’s disease. Regen. Med., 2016, 11(7), 629-646.
[http://dx.doi.org/10.2217/rme-2016-0032] [PMID: 27582416]

Hanafy, A.S.; Farid, R.M.; Helmy, M.W.; ElGamal, S.S. Pharmacological, toxicological and neuronal localization assessment of galantamine/chitosan complex nanoparticles in rats: future potential contribution in Alzheimer’s disease management. Drug Deliv., 2016, 23(8), 3111-3122.
[http://dx.doi.org/10.3109/10717544.2016.1153748] [PMID: 26942549]

Mittal, G.; Carswell, H.; Brett, R.; Currie, S.; Kumar, M.N. Development and evaluation of polymer nanoparticles for oral delivery of estradiol to rat brain in a model of Alzheimer’s pathology. J Cont Rel., 2011, 150(2), 220-228.
[http://dx.doi.org/10.1016/j.jconrel.2010.11.013]

Cao, X.; Hou, D.; Wang, L.; Li, S.; Sun, S.; Ping, Q.; Xu, Y. Effects and molecular mechanism of chitosan-coated levodopa nanoliposomes on behavior of dyskinesia rats. Biol. Res., 2016, 49(1), 32.
[http://dx.doi.org/10.1186/s40659-016-0093-4] [PMID: 27378167]

Arisoy, S.; Sayiner, O.; Comoglu, T.; Onal, D.; Atalay, O.; Pehlivanoglu, B. In vitro and in vivo evaluation of levodopa-loaded nanoparticles for nose to brain delivery. Pharm. Dev. Technol., 2020, 25(6), 735-747.
[http://dx.doi.org/10.1080/10837450.2020.1740257] [PMID: 32141798]

Vong, L.B.; Sato, Y.; Chonpathompikunlert, P.; Tanasawet, S.; Hutamekalin, P.; Nagasaki, Y. Self-assembled polydopamine nanoparticles improve treatment in Parkinson’s disease model mice and suppress dopamine-induced dyskinesia. Acta Biomater., 2020, 109, 220-228.
[http://dx.doi.org/10.1016/j.actbio.2020.03.021] [PMID: 32268242]

Yan, X.; Xu, L.; Bi, C.; Duan, D.; Chu, L.; Yu, X.; Wu, Z.; Wang, A.; Sun, K. Lactoferrin-modified rotigotine nanoparticles for enhanced nose-to-brain delivery: LESA-MS/MS-based drug biodistribution, pharmacodynamics, and neuroprotective effects. Int. J. Nanomedicine, 2018, 13, 273-281.
[http://dx.doi.org/10.2147/IJN.S151475] [PMID: 29391788]

Bhattamisra, S.K.; Shak, A.T.; Xi, L.W.; Safian, N.H.; Choudhury, H.; Lim, W.M.; Shahzad, N.; Alhakamy, N.A.; Anwer, M.K.; Radhakrishnan, A.K.; Md, S. Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson’s disease. Int. J. Pharm., 2020, 579, 119148.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119148] [PMID: 32084576]

Sridhar, V.; Gaud, R.; Bajaj, A.; Wairkar, S. Pharmacokinetics and pharmacodynamics of intranasally administered selegiline nanoparticles with improved brain delivery in Parkinson’s disease. Nanomedicine, 2018, 14(8), 2609-2618.
[http://dx.doi.org/10.1016/j.nano.2018.08.004] [PMID: 30171904]

Negro, S.; Boeva, L.; Slowing, K.; Fernandez-Carballido, A.; Garcia-García, L.; Barcia, E. Efficacy of Ropinirole-Loaded PLGA Microspheres for the Reversion of Rotenone- Induced Parkinsonism. Curr. Pharm. Des., 2017, 23(23), 3423-3431.
[PMID: 27779080]

Raj, R.; Wairkar, S.; Sridhar, V.; Gaud, R. Pramipexole dihydrochloride loaded chitosan nanoparticles for nose to brain delivery: Development, characterization and in vivo anti-Parkinson activity. Int. J. Biol. Macromol., 2018, 109, 27-35.
[http://dx.doi.org/10.1016/j.ijbiomac.2017.12.056] [PMID: 29247729]

Md, S.; Khan, R.A.; Mustafa, G.; Chuttani, K.; Baboota, S.; Sahni, J.K. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. Euro. J. Pharma. Sci., 2013, 48(3), 393-405.
[http://dx.doi.org/10.1016/j.ejps.2012.12.007]

Sharma, S.; Lohan, S.; Murthy, R.S.R. Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery. Drug Dev. Ind. Pharm., 2014, 40(7), 869-878.
[http://dx.doi.org/10.3109/03639045.2013.789051] [PMID: 23600649]

Gambaryan, P.Y.; Kondrasheva, I.G.; Severin, E.S.; Guseva, A.A.; Kamensky, A.A. Increasing the Effciency of Parkinson’s Disease Treatment Using a poly(lactic-co-glycolic acid) (PLGA) Based L-DOPA Delivery System. Exp. Neurobiol., 2014, 23(3), 246-252.
[http://dx.doi.org/10.5607/en.2014.23.3.246] [PMID: 25258572]

Leyva-Gómez, G.; Cortés, H.; Magaña, J.J.; Leyva-García, N.; Quintanar-Guerrero, D.; Florán, B. Nanoparticle technology for treatment of Parkinson’s disease: the role of surface phenomena in reaching the brain. Drug Discov. Today, 2015, 20(7), 824-837.
[http://dx.doi.org/10.1016/j.drudis.2015.02.009] [PMID: 25701281]

Esposito, E.; Mariani, P.; Ravani, L.; Contado, C.; Volta, M.; Bido, S.; Drechsler, M.; Mazzoni, S.; Menegatti, E.; Morari, M.; Cortesi, R. Nanoparticulate lipid dispersions for bromocriptine delivery: Characterization and in vivo study. Eur. J. Pharm. Biopharm., 2012, 80(2), 306-314.
[http://dx.doi.org/10.1016/j.ejpb.2011.10.015] [PMID: 22061262]

Tsai, M.J.; Huang, Y.B.; Wu, P.C.; Fu, Y.S.; Kao, Y.R.; Fang, J.Y.; Tsai, Y.H. Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. J. Pharm. Sci., 2011, 100(2), 547-557.
[http://dx.doi.org/10.1002/jps.22285] [PMID: 20740670]

Wen, C.J.; Zhang, L.W.; Al-Suwayeh, S.A.; Yen, T.C.; Fang, J.Y. Theranostic liposomes loaded with quantum dots and apomorphine for brain targeting and bioimaging. Int. J. Nanomedicine, 2012, 7, 1599-1611.
[PMID: 22619515]

Hsu, S.H.; Wen, C.J.; Al-Suwayeh, S.A.; Chang, H.W.; Yen, T.C.; Fang, J.Y. Physicochemical characterization and in vivo bioluminescence imaging of nanostructured lipid carriers for targeting the brain: apomorphine as a model drug. Nanotechnology, 2010, 21(40), 405101.
[http://dx.doi.org/10.1088/0957-4484/21/40/405101] [PMID: 20823498]

Huang, R.; Han, L.; Li, J.; Ren, F.; Ke, W.; Jiang, C.; Pei, Y. Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles. J. Gene Med., 2009, 11(9), 754-763.
[http://dx.doi.org/10.1002/jgm.1361] [PMID: 19554623]

Martinez-Fong, D.; Bannon, M.J.; Trudeau, L.E.; Gonzalez-Barrios, J.A.; Arango-Rodriguez, M.L.; Hernandez-Chan, N.G.; Reyes-Corona, D.; Armendáriz-Borunda, J.; Navarro-Quiroga, I. NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson’s disease. Nanomedicine, 2012, 8(7), 1052-1069.
[http://dx.doi.org/10.1016/j.nano.2012.02.009] [PMID: 22406187]